| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -58.6 | -60.2 |
| Net income | -58.6 | -60.2 |
| EPS (diluted, $ a share) | $-0.64 | $-4.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KARD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kardigan, Inc.: key numbers
- Share price
- $12.85Close, Nov 16
- Market cap
- $1.2B
- Shares outstanding
- 93.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kardigan, Inc.
All →Kardigan Financial Results
Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.
- Term
- Q3 2026
“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”
Tassos Gianakakos, co-founder, chief executive officer and board chair
Kardigan Business Update
Kardigan, Inc. has completed enrollment for its Phase 2b KATALYST-AV trial evaluating ataciguat in patients with aortic stenosis. The company also updated its trial protocol to assess the primary endpoint of aortic valve calcium at week 48 instead of earlier, based on real-world data analysis of disease progression. Topline data from the trial is now expected in the second half of 2027.
Kardigan Leadership Change
Kardigan, Inc. appointed Kristin Reinke, currently Vice President of Finance at Google, to its Board of Directors and as chair of the Audit Committee. Simultaneously, founding board member Doug Giordano resigned from the Board and Audit Committee. Ms. Reinke will receive an initial stock option grant valued at $650,000 as part of her appointment.
- Counterparty
- Kristin Reinke